Clarivate to sell Life Sciences & Healthcare for $600M, to use proceeds to reduce debt

Clarivate agreed to sell its Life Sciences & Healthcare segment to Altaris for $600 million, with cash proceeds earmarked to reduce debt and sharpen focus on Academia & Government and Intellectual Property.

Key Highlights:

• Definitive agreement to divest LS&H to Altaris for $600M (≈$525M cash + $75M seller note).
• Clarivate will receive $500M at closing, $25M deferred, and a $75M seller note; proceeds to retire 2028/2029 notes.
• Transaction expected to close by year-end, subject to regulatory approvals and customary conditions.
• Company reaffirms full-year 2026 guidance; LS&H results will be reported as discontinued operations starting Q3.
• Company expects a ~$225–$250M non-cash goodwill impairment on LS&H that won’t affect 2026 outlook metrics.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.